Compare Recursion Pharmaceuticals Inc (RXRX) vs SOLAI Limited (SLAI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs SOLAI Limited — how do they compare? Recursion Pharmaceuticals Inc trades at $3.07 (market cap $1.53B), while SOLAI Limited trades at $3.72 (market cap $16.69M). The key difference: Recursion Pharmaceuticals Inc is far larger — about 91.7× SOLAI Limited's market cap. Which is the better fit depends on your goals.
| RXRX | SLAI | |
|---|---|---|
Market Cap | $1.53B | $16.69M |
Sector | Health | Technology |
52-Week High | $6.79 | $26.74 |
52-Week Low | $2.84 | $2.74 |
Enterprise Value | $946.50M | $16.33M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SLAI trades at $3.72 with no recent price movement, while facing NYSE delisting proceedings announced July 16, 2026. The company shows severe financial distress with negative gross profit margin of -44.87% and net income margin of -134.63% for 2025. Recent developments include a 7:1 reverse stock split effective June 2026 and acquisition of a 51% stake in NEURALAND. Technical indicators show mixed signals with an overall bullish trend but overbought RSI conditions.
The outlook remains highly speculative given delisting risks and persistent losses. Investment opportunity exists only for speculative traders betting on turnaround potential from recent acquisitions and AI product launches. Primary risks include imminent delisting, negative cash flow, and unsustainable financial performance that threatens ongoing operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About SOLAI Limited
SOLAI focuses on providing innovative AI-driven software solutions. The company leverages artificial intelligence to enhance digital experiences and optimize business processes for various industries.
Read more on SLAI →
